Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : GREAT STOCKS UNDER $15 -- Ignore unavailable to you. Want to Upgrade?

To: Bo Didley who wrote (107)	12/9/1998 9:11:00 PM
From: David K.	Read Replies (1) \| Respond to of 126

Biotech is certainly next to the net the most exciting and dangerous sector of the market. Some many of these companies have barely enough cash to keep them in business for more than a year. They need to raise more and more money. ASTM lost 3 million dollars and has only 11 million in cash left. The news on many of these companies sounds great but only a handful will be successful. Buy ten of them and maybe only one will be like SEPR. For us amateurs it is like shooting in the dark at a very small moving target somewhere in the room. I remember when Dr. K gave his highest recommendation to Autoimmune (Aimm) in April 97 at 14 which by May 97 was below 3 ( 2 7/16 today). Unless you have a beeline to the Almighty, spread your money around in biotech or get in and out fast.( Always be wary of the hype). PS One last story. At a party last year I met Dough , a brilliant scientist who had been working in the biotech industry for 5 years. I asked him what his favorite biotech stock was. Amylin (Amln) he said. At the time it was at 10. Today the stock is at 1/2. So much for news from the horse's mouth.

To: Bo Didley who wrote (107)	12/9/1998 9:17:00 PM
From: Kevin Clarke	Read Replies (1) \| Respond to of 126

BO, ALSO DON'T KEEP YOUR EYE OF ***ECHO*** lilikoi.com

To: Bo Didley who wrote (107)	12/9/1998 11:52:00 PM
From: David K.	Read Replies (1) \| Respond to of 126

The idea sounds great. However, isn't the company talking about a possibility rather than a reality? "........ the studies begin to demonstrate the POTENTIAL clinical benefits of the AastromReplicell(TM) System as we approach European market introduction of the product line for stem cell therapy. These POTENTIAL benefits include improving patient care and enabling transplants to be performed when they otherwise might not have been feasible." Chief Executive Douglas Armstrong said, ''The pivotal trial represents an extension of the earlier trial ... We BELIEVE the subsequent trial results will further demonstrate the clinical utility of the AastromReplicell System.'' God willing, we all hope that they will be completely successful in their endeavors. At the moment, it appears to be at the PR stage. Ride it up on the enthusiasm and take your profits before it goes back down (i.e if the enthusiasm continues for a few more days)